Evidence map›Paper›PMID 33028580›Full record

ArticleAnnals of the rheumatic diseases2021

Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement.

Kimberly Showalter, Robert Spiera, Cynthia Magro, Phaedra Agius, Viktor Martyanov, Jennifer M Franks, Roshan Sharma, Heather Geiger, Tammara A Wood, Yaxia Zhang and 5 more

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. [Social media-Chances and risks for rheumatology].Zeitschrift fur Rheumatologie · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Insights Into Systemic Sclerosis from Gene Expression Profiling.Current treatment options in rheumatology · 2021
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Kimberly ShowalterDepartment of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA showalterk@hss.edu.ORCID 0000-0001-9343-5545
Robert SpieraDepartment of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.
Cynthia MagroDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
Phaedra AgiusNew York Genome Center, New York, New York, USA.
Viktor MartyanovMolecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA.
Jennifer M FranksMolecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA.ORCID 0000-0003-2400-5431
Roshan SharmaNew York Genome Center, New York, New York, USA.
Heather GeigerNew York Genome Center, New York, New York, USA.
Tammara A WoodMolecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA.
Yaxia ZhangDepartment of Pathology, Hospital for Special Surgery, New York, New York, USA.
Caryn R HaleLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York, USA.
Jackie FinikDepartment of Medicine, Hospital for Special Surgery, New York, New York, USA.
Michael L WhitfieldMolecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA.ORCID 0000-0002-0862-6003
Dana E Orange *Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.ORCID 0000-0001-9859-7199
Jessica K Gordon *Department of Medicine, Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA.
Hospital for Special Surgery · USDartmouth College · USNew York Genome Center · USCornell University · USRockefeller University · US

Funding

Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesisP50AR060780 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LAFYATIS, ROBERT A. · 2011 to 2021
$14.9M
NIAMS NIH HHS P50 AR060780
6 · The paper itself

Abstract

objectiveWe sought to determine histologic and gene expression features of clinical improvement in early diffuse cutaneous systemic sclerosis (dcSSc; scleroderma).

methodsFifty-eight forearm biopsies were evaluated from 26 individuals with dcSSc in two clinical trials. Histologic/immunophenotypic assessments of global severity, alpha-smooth muscle actin (aSMA), CD34, collagen, inflammatory infiltrate, follicles and thickness were compared with gene expression and clinical data. Support vector machine learning was performed using scleroderma gene expression subset (normal-like, fibroproliferative, inflammatory) as classifiers and histology scores as inputs. Comparison of w-vector mean absolute weights was used to identify histologic features most predictive of gene expression subset. We then tested for differential gene expression according to histologic severity and compared those with clinical improvement (according to the Combined Response Index in Systemic Sclerosis).

resultsaSMA was highest and CD34 lowest in samples with highest local Modified Rodnan Skin Score. CD34 and aSMA changed significantly from baseline to 52 weeks in clinical improvers. CD34 and aSMA were the strongest predictors of gene expression subset, with highest CD34 staining in the normal-like subset (p<0.001) and highest aSMA staining in the inflammatory subset (p=0.016). Analysis of gene expression according to CD34 and aSMA binarised scores identified a 47-gene fibroblast polarisation signature that decreases over time only in improvers (vs non-improvers). Pathway analysis of these genes identified gene expression signatures of inflammatory fibroblasts.

conclusionCD34 and aSMA stains describe distinct fibroblast polarisation states, are associated with gene expression subsets and clinical assessments, and may be useful biomarkers of clinical severity and improvement in dcSSc.

Indexed as

Machine LearningSeverity of Illness IndexActinsAdultAntigens, CD34Clinical Trials as TopicCollagenFemaleFibroblastsForearmGene ExpressionHumansMaleMiddle AgedScleroderma, DiffuseSkinACTA2 protein, humanActinsAntigens, CD34Collagenautoimmune diseasesfibroblastsinflammationsclerodermasystemic

Identifiers

PMID33028580
PMCPMC8600653
OpenAlexW3091926370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.